XML 76 R18.htm IDEA: XBRL DOCUMENT
v3.23.1

Stockholders’ Equity | 12 Months Ended
--- | ---
Dec. 31, 2022
Equity [Abstract] |
Stockholders’ Equity | Note 11 – Stockholders’ Equity Shares authorized Upon formation, the total number of shares of all classes of stock that the Company is authorized to issue is seventy-five million (75,000,000) shares of common stock, par value $0.001 per share. Common stock During the year ended December 31, 2022, the Company issued 271,174 shares of common stock. On April 4, 2022, the Company issued 121,149 shares of its Common Stock to Boustead Securities LLC. (“Boustead”), issued pursuant to the cashless warrant exercise, exercised by Boustead on September 7, 2021 with an exercise price of $6.25 with the shares were valued at $1,776,044 upon the cashless exercise option of the warrants related to the completion of the Company’s August 30, 2021, public offering in connection with its listing on Nasdaq. On May 2, 2022, the Company issued 32,627 shares to consultants in exchange for professional services rendered. The shares were valued at $154,709 based on the closing price of the Company’s common stock on the dates that the shares were deemed earned, according to the agreements. On August 17, 2022, the Company issued 54,898 shares to two of the board members who exercised their options. On August 22, 2022, the Company issued 62,500 shares to employee based on the Restricted Stock Award Agreements (see Employee compensation). During the year ended December 31, 2021, the Company issued 2,300,000 shares of common stock. On September 2, 2021, the Company closed its initial public offering (“IPO”) under a registration statement effective August 30, 2021, in which it issued and sold 2,000,000 shares of its Common Stock at a purchase price of $5.00 per share. On September 2, 2021, the Company closed on the IPO’s overallotment option, selling an additional 300,000 shares of Common Stock to the IPO’s underwriters at the public offering price of $5.00 per share. The Company received net proceeds of approximately $10.3 million from the IPO after deducting underwriting fee and offering expenses. As of December 31, 2022 and 2021, the Company had 43,530,915 and 43,259,741 shares of common stock issued and outstanding, respectively. Treasury stock On August 10, 2022, the Company entered a stock purchase agreement with a private shareholder to repurchase 400,000 shares of its common stock for $2,000,000 and placed it in treasury. The private shareholder transferred the shares on October 4, 2022, forming a binding agreement, and on October 6, 2022, the Company wired the first $1,000,000 of the purchase price. The remaining $1,000,000 was due on or before February 6, 2023. This $1,000,000 is still not paid off as of the filing date. Shares to be issued for compensation The Company entered into agreements with third party consultants for financing and management consulting. The Company has incurred consulting service fees paid in cash amounting to $8,000 for the year ended December 31, 2022, which the Company intends to issue stock as compensation for services rendered. Expenses incurred and paid in shares as of December 31, 2022 and 2021 amounted to $8,000 and $48,000, respectively. On August 30, 2021, the Company entered into a Representative Common Stock Purchase Warrant agreement (“Warrant Agreement”) with its placement agent, Boustead Securities LLC. (“Boustead”) for 161,000 shares and the exercise price is $6.25. Boustead exercised the warrants on September 7, 2021. The fair value of the warrants was $1,041,670 and $2,326,450 as of August 30 and September 7, 2021, respectively. For the year ended December 31, 2022 and 2021, the Company recorded a loss from change in the fair value of warrant liability which amounted to a difference of $0 and $1,284,780, respectively. These warrants were valued using a Black-Scholes pricing model with the following assumptions:
Schedule of warrant assumptions |  |  |  |  |  |
|  | August 30, 2021 (Initial |  |  | September 7, |
|  | Measurement) |  |  | 2021 |
Risk-free interest rate |  |  | 0.77% |  |  |  | 0.82% |
Expected term |  |  | 5 years |  |  |  | 5 years |
Expected volatility |  |  | 194.37% |  |  |  | 204.27% |
Expected dividend yield |  |  | 0% |  |  |  | 0% |
Fair value of units (using Black-Scholes) |  | $ | 6.47 |  |  | $ | 14.45 |
This Warrant Agreement allowed for cashless exercise option, which is calculated by the percentage difference between exercise and trading price, which resulted in a reduced number of warrants being exercisable. On September 7, 2021, Boustead exercised 121,149 warrants with fair value of $1,776,044 upon cashless exercise option of warrants related to completion of the Company’s public offering. The shares will be issued six months after these warrants have been exercised. For the year ended December 31, 2022 and 2021, the Company has a gain on settlement of derivative liability which amounted to $0 and $550,406, respectively. Shares to be issued as of December 31, 2022 and December 31, 2021 amounted to $0 and $1,776,044, respectively. Employee compensation On February 11, 2022 (“Vesting Date”), the Company entered into a Restricted Stock Award Agreement (“Award Agreement”) with eight employees for 280,000 shares of the $0.001 par value voting common stock subject to the terms and to the fulfillment of the conditions set in the Company’s equity incentive plan. The first 20% of the restricted shares was granted and vested on February 11, 2022 (the “Vesting Date”). Twenty percent of the restricted shares will vest on each anniversary of the Vesting Date until fourth anniversary of the Vesting Date. There were 56,000 shares granted on February 11, 2022. The fair value of above employee compensation was $588,560 as of December 31, 2022. In November 2021, the Company entered into a one-year employment agreement with VP of Finance and Head of Investor Relations of the Company, pursuant to which the Company rewards a 10,000-share bonus consisting of shares of $0.001 par value voting common stock, which will be granted in 2,500 blocks every quarter based on certain performance metrics. In November 2022, the Company entered into an amendment agreement to amend performance metrics. In October 2022, the Company entered into a employee agreement with VP of the Company, pursuant to which the Company rewards a 10,000-share bonus consisting of shares of $0.001 par value voting common stock, which will be granted in 2,500 shares every quarter. During the years ended December 31, 2022 and 2021, the total employee compensation amount for all employees in the company, was $711,975 and $0, respectively. The Company issued 62,500 shares with total value of $663,900 for employee compensation as of the year ended December 31, 2022. During the year ended December 31, 2022, the Company recognized employee compensation in amount of $107,390 for the fixed salary of the VP of Finance and $16,025 for the VP. The Company has incurred expenses amount of $48,075 employee compensation for the year ended December 31, 2022 and not yet paid in shares as of December 31, 2022. Stock options On August 6, 2019, each member of the Board was granted 30,000 options to purchase shares at $5.70 per share. On January 4, 2021, each member of the Board was granted 15,000 options to purchase shares at $3.00 per share. On December 31, 2021, each member of the Board was granted 15,000 options to purchase shares at $8.86 per share. On December 30, 2022, each member of the Board was granted 15,000 options to purchase shares at $6.41 per share. As of December 31, 2022, there were 410,041 options granted, 305,616 options vested, 104,425 options unvested, and 410,041 outstanding stock options. For the years ended December 31, 2022 and 2021, the Company’s stock option compensation expenses amounted to $849,043 and $429,856, respectively. The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions:
Schedule of option assumptions |  |  |  |  |  |
|  | December 31, 2022 |  |  | December 31, 2021 |
Risk-free interest rate |  |  | 4.22% |  |  |  | 0.93 – 1.52% |
Expected life of the options |  |  | 3 years |  |  |  | 10 years |
Expected volatility |  |  | 42.63% |  |  |  | 122.93 – 148.18% |
Expected dividend yield |  |  | 0% |  |  |  | 0% |
The following is a summary of options activity from December 31, 2021 to December 31, 2022:
Schedule of options activity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Options |  | Shares |  |  | Weighted average exercise price |  |  | Weighted Average Remaining Contractual Life |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2021 |  |  | 420,000 |  |  | $ | 5.82 |  |  |  | 8.56 |  |  |  | – |
Granted |  |  | 105,000 |  |  | $ | 6.41 |  |  |  | – |  |  |  | – |
Exercised |  |  | (107,500 | ) |  | $ | 5.46 |  |  |  | – |  |  |  | – |
Cancelled or forfeited |  |  | (7,459 | ) |  | $ | 8.86 |  |  |  | – |  |  |  | – |
Outstanding at December 31, 2022 |  |  | 410,041 |  |  | $ | 5.93 |  |  |  | 8.04 |  |  |  | 362,250 |
Exercisable at December 31, 2022 |  |  | 305,616 |  |  | $ | 5.87 |  |  |  | 7.58 |  |  |  | 362,250 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration